Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma

NCT03682796 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Lymphoma, Mantle-Cell
Lymphoma, Marginal Zone
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Follicular

Interventions

DRUG: TRPH-222

Sponsor

Triphase Research and Development III Corp.